Matricelf Ltd is an Israel-based company engaged in the biotechnology sector. The Company operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The Company focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinsonâ€™s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
31/07/26	ILA 248.20	+1.31%	787
30/07/26	ILA 245.00	-0.57%	111,101
29/07/26	ILA 246.40	-1.60%	33,126
28/07/26	ILA 250.40	-2.03%	51,939
27/07/26	ILA 255.60	+2.53%	78,524

Delayed Quote TEL AVIV STOCK EXCHANGE

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 18:44:13 31/07/2026 HKT			5-day change	1st Jan Change
248.20 ^ILa	+1.31%		-0.44%	-54.95%

07-09	Matricelf Ltd. Receives Approval to Begin Patient Identification and Blood Collection for Planned First-In-Human Spinal Cord Injury Study	CI
06-22	Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord Injury	CI

Market Cap	72.59M 7.26B 23.75M 20.57M 19.17M 17.68M 33.44M 2.27B 33.71M 226M 88.53M 1.13B 89.2M 87.24M 3.74B	P/E 2024	-3.74x	P/E 2025	-3.65x
Enterprise Value	52.45M 5.24B 17.16M 14.86M 13.85M 12.78M 24.16M 1.64B 24.36M 163M 63.97M 816M 64.45M 63.03M 2.7B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	77.85%	Yield 2024 *	-	Yield 2025	-

07-09	Matricelf Ltd. Receives Approval to Begin Patient Identification and Blood Collection for Planned First-In-Human Spinal Cord Injury Study	CI
06-22	Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord Injury	CI
06-17	Matricelf Completes GLP Safety Study for Engineered Neural Tissue Implant	CI
03-30	Matricelf Ltd. Enters into Collaborative Research Agreement with CiRA Foundation	CI
03-25	Matricelf Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-24	Matricelf and Sheba Medical Center Enter Strategic Collaboration to Advance First in Human Clinical Program in Spinal Cord Injury	CI
03-24	Matricelf Ltd Auditor Raises 'Going Concern' Doubt	CI
03-04	Matricelf Ltd. Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile Of Its Personalized Spinal Cord Implant	CI
03-03	Matricelf Ltd. Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	CI
03-03	Matricelf Ltd. (Tase Mtlf) signs MoU to establish subsidiary for commercialization of Parkinson's disease therapy	RE
02-27	Matricelf Ltd Appoints Ron Mayron as Active Chairman of the Board of Directors	CI
03/08/25	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
11/03/25	Cellino and Matricelf Announce Global Collaboration to Scale Personalized Spinal Cord Injury Treatments	CI

07-09	Matricelf Continues Clinical Execution with Patient Enrollment Preparation Following GLP Safety Success and GMP Manufacturing Milestones	PR
06-23	Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury	AQ
03-03	Matricelf Ltd. (TASE: MTLF) Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	PR
03-02	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	AQ
02-27	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	PR

Matricelf Ltd Stock

Stocks

MTLF

IL0011767915

Biotechnology & Medical Research

Valuation: Matricelf Ltd

Chart: Matricelf Ltd

Latest news : Matricelf Ltd

Press Releases: Matricelf Ltd

Quotes and Performance

Course Extremes

Managers and Directors: Matricelf Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+1.31%
1 week	-0.44%
1 month	-8.92%
3 months	-11.89%
6 months	-52.41%
Current year	-54.95%

1 week	242.2	260
1 month	233.1	273
Current year	212	853
1 year	204	853
3 years	204	853
5 years	204	1,555
10 years	204	1,555

Manager	Title	Age	Since
Asaf Toker CEO	Chief Executive Officer	54	01/06/2019
Tal Dvir CTO	Chief Tech/Sci/R&D Officer	51	01/06/2019
Alon Sinai COO	Chief Operating Officer	59	01/07/2019

Director	Title	Age	Since
Alon Sinai BRD	Director/Board Member	59	01/07/2019
Tal Dvir BRD	Director/Board Member	51	01/06/2019
Stanley Hirsch BRD	Director/Board Member	68	27/07/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MATRICELF LTD	+1.31%	-0.44%	+17.24%	-42.47%	23.67M
LONZA GROUP AG	-1.40%	+2.59%	-1.71%	+11.28%	48.53B
REVOLUTION MEDICINES, INC.	-2.41%	-0.90%	+411.96%	+495.33%	39.87B
IQVIA HOLDINGS INC.	-1.16%	+12.96%	+28.81%	+7.25%	38.68B
BEONE MEDICINES AG	-1.88%	-3.03%	+5.69%	+53.00%	35.13B
CELLTRION, INC.	-1.74%	+5.12%	+14.44%	+41.77%	29.79B
MEDPACE HOLDINGS, INC.	-0.21%	-4.04%	+36.40%	+125.75%	16.11B
ASCENDIS PHARMA A/S	-2.85%	-3.92%	-	-	16.08B
EUROFINS SCIENTIFIC SE	-0.64%	+2.65%	+3.40%	+13.11%	13.61B
ICON PUBLIC LIMITED COMPANY	-1.19%	-1.32%	-1.73%	-34.37%	12.62B
Average	-1.22%	+0.90%	+57.17%	+74.52%	25.04B
Weighted average by Cap.	-1.60%	+2.03%	+79.78%	+108.60%

	2024	2025
Net sales	-	-
Net income	-15.58M -1.56B -5.1M -4.42M -4.11M -3.8M -7.18M -486M -7.24M -48.44M -19.01M -242M -19.15M -18.73M -802M	-27.82M -2.78B -9.1M -7.88M -7.35M -6.78M -12.82M -868M -12.92M -86.48M -33.93M -433M -34.19M -33.44M -1.43B
Net Debt	-10.68M -1.07B -3.49M -3.03M -2.82M -2.6M -4.92M -333M -4.96M -33.2M -13.03M -166M -13.12M -12.84M -550M	-20.14M -2.01B -6.59M -5.71M -5.32M -4.91M -9.28M -629M -9.35M -62.6M -24.56M -313M -24.75M -24.21M -1.04B